<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">44534900X</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180317142838.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170323e20110801xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/s11192-011-0396-8</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/s11192-011-0396-8</subfield>
  </datafield>
  <datafield tag="100" ind1="1" ind2=" ">
   <subfield code="a">Chen</subfield>
   <subfield code="D">Yu-Shan</subfield>
   <subfield code="u">Department of Business Administration, National Taipei University, 151, University Rd., San Shia, 237, Taipei, Taiwan</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
   <subfield code="a">Using patent analysis to explore corporate growth</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[Yu-Shan Chen]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">This study applies patent analysis to discuss the influences of the three aspects of patent trait—a firm's revealed technology advantage in its most important technological field (RTAMIT), relative patent position in its most important technological field (RPPMIT), and patent share in its most important technological field (PSMIT)—upon corporate growth and discusses the moderation effect of relative growth rate of its most important technological field (RGRMIT) in the American pharmaceutical industry. The results demonstrate that the three relationships between corporate growth and the three aspects of patent trait are positive, and verify that RGRMIT moderates the three relationships. This study suggests that pharmaceutical companies should enhance their R&amp;D capabilities, the degree of leading position, and concentration of R&amp;D investment in their most important technological fields to increase their growth. Finally, this study classifies the pharmaceutical companies into four types, and provides some suggestions to them.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Akadémiai Kiadó, Budapest, Hungary, 2011</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Patent analysis</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Corporate growth</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Revealed technology advantage (RTA)</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Relative patent position (RPP)</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Patent share (PS)</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Scientometrics</subfield>
   <subfield code="d">Springer Netherlands</subfield>
   <subfield code="g">88/2(2011-08-01), 433-448</subfield>
   <subfield code="x">0138-9130</subfield>
   <subfield code="q">88:2&lt;433</subfield>
   <subfield code="1">2011</subfield>
   <subfield code="2">88</subfield>
   <subfield code="o">11192</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/s11192-011-0396-8</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/s11192-011-0396-8</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">100</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Chen</subfield>
   <subfield code="D">Yu-Shan</subfield>
   <subfield code="u">Department of Business Administration, National Taipei University, 151, University Rd., San Shia, 237, Taipei, Taiwan</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Scientometrics</subfield>
   <subfield code="d">Springer Netherlands</subfield>
   <subfield code="g">88/2(2011-08-01), 433-448</subfield>
   <subfield code="x">0138-9130</subfield>
   <subfield code="q">88:2&lt;433</subfield>
   <subfield code="1">2011</subfield>
   <subfield code="2">88</subfield>
   <subfield code="o">11192</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
